HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4480-4483

  Wang, Guangyi ^a   Lei, Huoxing ^b   Wang, Xiaofang ^b   Das, Debasis ^b   Hong, Jian ^b   Mackinnon, Colin H ^c   Coulter, Thomas S ^c   Montalbetti, Christian A G N ^c   Mears, Richard ^c   Gai, Xinjie ^c   Bailey, Sarah E ^c   Ruhrmund, Donald ^a   Hooi, Lisa ^a   Misialek, Shawn ^a   Rajagopalan, P T Ravi ^a   Cheng, Robert K Y ^c   Barker, John J ^c   Felicetti, Brunella ^c   Schönfeld, Dorian L ^c   Stoycheva, Antitsa ^a   Buckman, Brad O ^a   Kossen, Karl ^a   Seiwert, Scott D ^a   Beigelman, Leonid ^a   more..

^a InterMune Inc   (United States)

^b WUXI APPTEC   (China)

^c EVOTEC UK LTD   (United Kingdom)

Author keywords

Benzothiadiazine; HCV NS5B polymerase inhibitors

Indexed keywords

[1,1 DIOXO 2H (1,2,4) BENZOTHIADIAZIN 3 YL] AZOLO (1,5 A) PYRIDINE; ANTIVIRUS AGENT; AZOLO [1,5 A] PYRIDMIDINE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; REPLICON; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; AZOLES; BENZOTHIADIAZINES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PYRIDINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 67649974970     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.022     Document Type: Article

References (18)

1. Shepard C.W., Finelli L., and Alter M.J. Lancet Infect. Dis. 5 (2005) 558
2. WHO, Hepatitis C. Incidence/Epidemiology under Section Surveillance and Control 2002. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html.
3. Manns M.P., Wedemeyer H., and Cornberg M. Gut 55 (2006) 1350
4. Lindenbach B.D., and Rice C.M. Nature 436 (2005) 933
5. Beaulieu P.L. Curr. Opin. Invest. Drugs 8 (2007) 614
6. Rönn R., and Sandström A. Curr. Top. Med. Chem. 8 (2008) 533
7. Tramontano E. Mini-Rev. Med. Chem. 8 (2008) 1298
8. Krueger A.C., Madigan D.L., Green B.E., Hutchinson D.K., Jiang W.W., Kati W.M., Liu Y., Maring C.J., Masse S.V., McDaniel K.F., Middleton T.R., Mo H., Molla A., Montgomery D.A., Ng T.I., and Kempf D.J. Bioorg. Med. Chem. Lett. 17 (2007) 2289
9. Ruebsam L., Webber S.E., Tran M.T., Tran C.V., Murphy D.E., Zhao J., Dragovich P.S., Kim S.H., Li L.-S., Zhou Y., Han Q., Kissinger C.R., Showalter R.E., Lardy M., Shah A.M., Tsan M., Patel R., LeBrun L.A., Kamran R., Sergeeva M.V., Bartkowski D.M., Nolan T.G., Norris D.A., and Kirkovsky L. Bioorg. Med. Chem. Lett. 18 (2008) 3616
10. Chen C.-M., He Y., Lu L., Lim H.B., Tripathi R.L., Middleton T., Hernandez L.E., Beno D.W.A., Long M.A., Kati W.M., Bosse T.D., Larson D.P., Wagner R., Lanford R.E., Kohlbrenner W.E., Kempf D.J., Pilot-Matias T.J., and Molla A. Antimicrob. Agents Chemother. 51 (2007) 4290
11. Compounds 3a and 3b were synthesized and evaluated independently before a patent application (Ruebsam, F.; Dragovich, P. US Patent Application 2008/0227774 A1) was published.
12. Imai Y., Mochizuki A., and Kakimoto M. Synthesis 10 (1983) 851
13. 2, B: IPA (0.25% DEA), A:B = 60:40 at 40 ml/min. Column temp.: 35 °C.
14. Tan, H.; Wang, G.; Moy, C.; Kossen, K.; Rajagopalan, R.; Misialek, S.; Ruhrmund, D.; Hooi, L.; Snarskaya, N.; Stoycheva, A.; Buckman, B.; Seiwert, S.; Beigelman, L. A poster presentation (# 936) at 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, 2009. A co-crystal structure of 3a and NS5B was presented.
15. A PDB file for the NS5B polymerase/inhibitor complex (PDB identifier 3H98) has been deposited with the Protein Data Bank.
16. Tedesco R., Shaw A.N., Bambal R., Chai D., Concha N.O., Darcy M.G., Dhanak D., Fitch D.M., Gates A., Gerhardt W.G., Halegoua D.L., Han C., Hofmann G.A., Johnston V.K., Kaura A.C., Liu N., Keenan R.M., Lin-Goerke J., Sarisky R.T., Wiggall K.J., Zimmerman M.N., and Duffy K.J. J. Med. Chem. 49 (2006) 971
17. 50 values. Z prime values under these conditions were >0.6.
18. 50 values.